Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D02REJ
|
|||
| Former ID |
DIB011251
|
|||
| Drug Name |
JNJ-17216498
|
|||
| Synonyms |
Histamine H3 antagonist (oral, narcolepsy) J&J
Click to Show/Hide
|
|||
| Indication | Narcolepsy [ICD-11: 7A20; ICD-10: G47.4; ICD-9: 347] | Phase 2 | [1] | |
| Company |
Johnson & Johnson
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Histamine H3 receptor (H3R) | Target Info | Antagonist | [2] |
| KEGG Pathway | Neuroactive ligand-receptor interaction | |||
| Reactome | Histamine receptors | |||
| G alpha (i) signalling events | ||||
| WikiPathways | Monoamine Transport | |||
| GPCRs, Class A Rhodopsin-like | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00424931) A Safety and Effectiveness Study of a Single Dose of JNJ-17216498 in Patients With Narcolepsy. U.S. National Institutes of Health. | |||
| REF 2 | Acute wake-promoting actions of JNJ-5207852, a novel, diamine-based H3 antagonist. Br J Pharmacol. 2004 Nov;143(5):649-61. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.